Pregnane X receptor mediates Sorafenib resistance in advanced hepatocellular carcinoma.
| Author | |
| Abstract |
:
Kinase inhibitor sorafenib is the most widely used drug for advanced HCC clinical treatment nowadays. However, sorafenib administration is only effective for a small portion of HCC patients, and the majority develop sorafenib-resistance during treatment. Thus, it is urgent to discover the endogenous mechanism and identify new pharmaceutical targets of sorafenib-resistance. |
| Year of Publication |
:
2018
|
| Journal |
:
Biochimica et biophysica acta
|
| Date Published |
:
2018
|
| ISSN Number |
:
0006-3002
|
| URL |
:
http://linkinghub.elsevier.com/retrieve/pii/S0304-4165(18)30016-3
|
| DOI |
:
10.1016/j.bbagen.2018.01.011
|
| Short Title |
:
Biochim Biophys Acta
|
| Download citation |
